The Dutch population screening programme for breast cancer has been running for nearly 35 years and has extensively proven its worth. Although there have been no major changes to the programme design in recent years, it is important to continue to closely monitor screening outcomes and evaluate new developments in a timely manner, to see whether the screening programme could be further improved.

The Dutch screening programme is continuously monitored and regularly evaluated. For the past few years, the Netherlands Comprehensive Cancer Organisation (IKNL) has been responsible for assessing/reporting key indicators, enabling short-cycle monitoring of the programme. The Dutch Expert Centre for Screening (LRCB) is responsible for continuous quality assurance and training of professionals with regard to the execution of the screening programme.